---
title: 'Sanofi/Takeda, UniQure & CSL, Fog Pharma, Merck + Imago'
type: 'episode'
url: 'https://doc.social/episodes/sanofi-takeda-uniqure-csl-fog-pharma-merck-imago'
show: 'Life Science Today'
show_url: 'https://doc.social/podcasts/life-science-today'
published: '2022-11-30'
audio: 'unavailable — the host retired the file'
---

# Sanofi/Takeda, UniQure & CSL, Fog Pharma, Merck + Imago

Vaccine hesitancy, the most expensive gene therapy in the world, a $178M series D, and a $1.3B buyoutFind out more athttps://LifeScienceTodayPodcast.comStory ReferencesSanofi/TakedaUniQure & CSLFog PharmaMerck + Imago About the ShowLife…

## Summary

Vaccine hesitancy, the most expensive gene therapy in the world, a $178M series D, and a $1.3B buyout

**Find out more at
**[https://LifeScienceTodayPodcast.com
](https://lifesciencetodaypodcast.com/)
**Story References**
[Sanofi/Takeda](https://www.biospace.com/article/fda-grants-priority-review-to-takedas-dengue-vaccine/?s=69)
[UniQure & CSL
](https://www.biospace.com/article/releases/uniqure-announces-fda-approval-of-first-gene-therapy-for-adults-with-hemophilia-b/)[Fog Pharma
](https://www.biospace.com/article/releases/fogpharma-announces-178-million-series-d-financing-to-advance-pipeline-of-first-in-class-helicon-polypeptide-therapeutics-targeting-major-cancer-drivers/?s=86)[Merck + Imago **
**](https://www.biospace.com/article/merck-acquires-imago-and-its-lsd1-inhibitors-in-1-3b-deal/?s=79)
**About the Show
**Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.